Biomarkers /
JAK2
Overview
JAK2 (Janus kinase 2) encodes for tyrosine-protein kinase JAK2, a protein tyrosine kinase involved in cytokine receptor signaling. Mutations in JAK2 have been identified in ALL and other hematologic malignancies.
JAK2 is altered in 2.65% of all cancers with lung adenocarcinoma, myeloproliferative neoplasm, breast invasive ductal carcinoma, polycythemia vera, and colon adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in JAK2 are JAK2 Mutation (2.05%), JAK2 Exon 14 Mutation (0.94%), JAK2 V617F (1.11%), JAK2 Loss (0.30%), and JAK2 Amplification (0.29%) [3].
Clinical Trials
Significance of JAK2 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.